Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) has a cash flow conversion efficiency ratio of 0.040x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩3.89 Billion ≈ $2.63 Million USD) by net assets (₩98.41 Billion ≈ $66.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Daishin Balance No.6 Special Purpose Acq total liabilities for a breakdown of total debt and financial obligations.
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spero Therapeutics Inc
NASDAQ:SPRO
|
0.658x |
|
Tribeca Global Natural Resources Ltd
AU:TGF
|
-0.103x |
|
Prosafe SE
OL:PRS
|
-0.021x |
|
UBM Development AG
VI:UBS
|
-0.015x |
|
Peninsula Energy Ltd
AU:PEN
|
-0.085x |
|
Bank Mnc Internasional Tbk
JK:BABP
|
-0.183x |
|
Fortinova Fastigheter AB Series B
ST:FNOVA-B
|
0.015x |
|
Masterflex SE
F:MZX
|
0.083x |
Annual Cash Flow Conversion Efficiency for Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (2020–2024)
The table below shows the annual cash flow conversion efficiency of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see Daishin Balance No.6 Special Purpose Acq stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩97.42 Billion ≈ $66.02 Million |
₩10.04 Billion ≈ $6.80 Million |
0.103x | +3006.31% |
| 2023-12-31 | ₩97.46 Billion ≈ $66.04 Million |
₩-345.45 Million ≈ $-234.11K |
-0.004x | +94.56% |
| 2022-12-31 | ₩92.32 Billion ≈ $62.57 Million |
₩-6.02 Billion ≈ $-4.08 Million |
-0.065x | -278.21% |
| 2021-12-31 | ₩83.15 Billion ≈ $56.35 Million |
₩3.04 Billion ≈ $2.06 Million |
0.037x | -87.53% |
| 2020-12-31 | ₩32.23 Billion ≈ $21.84 Million |
₩9.46 Billion ≈ $6.41 Million |
0.294x | -- |
About Daishin Balance No.6 Special Purpose Acquisition Co. Ltd
KUKJEON PHARMACEUTICAL Co., Ltd operates as a chemical total solutions provider in South Korea. It provides various chemical-based products and services; and after-sales services, such as research and development, production, quality control, and DMF services. The company manufactures active pharmaceutical ingredients; and offers molecular design and technical support. It develops electronic mate… Read more